These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Computable Phenotype Implementation for a National, Multicenter Pragmatic Clinical Trial: Lessons Learned From ADAPTABLE. Ahmad FS; Ricket IM; Hammill BG; Eskenazi L; Robertson HR; Curtis LH; Dobi CD; Girotra S; Haynes K; Kizer JR; Kripalani S; Roe MT; Roumie CL; Waitman R; Jones WS; Weiner MG Circ Cardiovasc Qual Outcomes; 2020 Jun; 13(6):e006292. PubMed ID: 32466729 [TBL] [Abstract][Full Text] [Related]
3. The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease. Johnston A; Jones WS; Hernandez AF Curr Cardiol Rep; 2016 Aug; 18(8):81. PubMed ID: 27423939 [TBL] [Abstract][Full Text] [Related]
4. Administrative claims data to support pragmatic clinical trial outcome ascertainment on cardiovascular health. Ma Q; Chung H; Shambhu S; Roe M; Cziraky M; Jones WS; Haynes K Clin Trials; 2019 Aug; 16(4):419-430. PubMed ID: 31081367 [TBL] [Abstract][Full Text] [Related]
5. Validation of Cardiovascular End Points Ascertainment Leveraging Multisource Electronic Health Records Harmonized Into a Common Data Model in the ADAPTABLE Randomized Clinical Trial. Marquis-Gravel G; Hammill BG; Mulder H; Roe MT; Robertson HR; Wruck LM; Sharlow A; Harris DF; Pohlman FW; Hernandez AF; Jones WS Circ Cardiovasc Qual Outcomes; 2021 Dec; 14(12):e008190. PubMed ID: 34886680 [TBL] [Abstract][Full Text] [Related]
6. Outcomes among patients with peripheral artery disease in the Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) study. Weissler EH; Stebbins A; Wruck L; Muñoz D; Gupta K; Girotra S; Whittle J; Benziger CP; Polonsky TS; Bradley SM; Hammill BG; Merritt JG; Zemon DN; Hernandez AF; Jones WS Vasc Med; 2023 Apr; 28(2):122-130. PubMed ID: 37025023 [TBL] [Abstract][Full Text] [Related]
7. Streamlining the institutional review board process in pragmatic randomized clinical trials: challenges and lessons learned from the Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) trial. Marquis-Gravel G; Robertson H; Jones WS; Riley D; Ford DE; Crenshaw D; Joosten YA; Rudov L; Hernandez AF; Hess R Trials; 2021 Jan; 22(1):90. PubMed ID: 33494785 [TBL] [Abstract][Full Text] [Related]
8. Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary Analysis. Farrant M; Easton JD; Adelman EE; Cucchiara BL; Barsan WG; Tillman HJ; Elm JJ; Kim AS; Lindblad AS; Palesch YY; Zhao W; Pauls K; Walsh KB; Martí-Fàbregas J; Bernstein RA; Johnston SC JAMA Netw Open; 2019 Sep; 2(9):e1910769. PubMed ID: 31490536 [TBL] [Abstract][Full Text] [Related]
9. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325 [TBL] [Abstract][Full Text] [Related]
10. Concordance Between Patient-Reported Health Data and Electronic Health Data in the ADAPTABLE Trial. O'Brien EC; Mulder H; Jones WS; Hammill BG; Sharlow A; Hernandez AF; Curtis LH JAMA Cardiol; 2022 Dec; 7(12):1235-1243. PubMed ID: 36322059 [TBL] [Abstract][Full Text] [Related]
12. Role of health plan administrative claims data in participant recruitment for pragmatic clinical trials: An Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) example. Shi Q; Shambhu S; Marshall A; Rose-Kennedy E; Robertson H; Paullin M; Jones WS; Cziraky M; Haynes K Clin Trials; 2020 Apr; 17(2):212-222. PubMed ID: 32009464 [TBL] [Abstract][Full Text] [Related]
13. Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). Bonaca MP; Goto S; Bhatt DL; Steg PG; Storey RF; Cohen M; Goodrich E; Mauri L; Ophuis TO; Ruda M; Špinar J; Seung KB; Hu D; Dalby AJ; Jensen E; Held P; Morrow DA; Braunwald E; Sabatine MS Circulation; 2016 Sep; 134(12):861-71. PubMed ID: 27576775 [TBL] [Abstract][Full Text] [Related]
14. Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trial. Mrdovic I; Savic L; Krljanac G; Asanin M; Cvetinovic N; Brdar N; Stojanovic M; Djuricic N; Stankovic S; Marinkovic J; Perunicic J J Interv Cardiol; 2013 Jun; 26(3):221-7. PubMed ID: 23373620 [TBL] [Abstract][Full Text] [Related]
15. Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial. Tillman H; Johnston SC; Farrant M; Barsan W; Elm JJ; Kim AS; Lindblad AS; Palesch YY; Easton JD JAMA Neurol; 2019 Jul; 76(7):774-782. PubMed ID: 31034032 [TBL] [Abstract][Full Text] [Related]
17. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. Watanabe H; Domei T; Morimoto T; Natsuaki M; Shiomi H; Toyota T; Ohya M; Suwa S; Takagi K; Nanasato M; Hata Y; Yagi M; Suematsu N; Yokomatsu T; Takamisawa I; Doi M; Noda T; Okayama H; Seino Y; Tada T; Sakamoto H; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Hanaoka KI; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T; JAMA; 2019 Jun; 321(24):2414-2427. PubMed ID: 31237644 [TBL] [Abstract][Full Text] [Related]
18. Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial. Chichareon P; Modolo R; Kerkmeijer L; Tomaniak M; Kogame N; Takahashi K; Chang CC; Komiyama H; Moccetti T; Talwar S; Colombo A; Maillard L; Barlis P; Wykrzykowska J; Piek JJ; Garg S; Hamm C; Steg PG; Jüni P; Valgimigli M; Windecker S; Onuma Y; Mehran R; Serruys PW JAMA Cardiol; 2020 Jan; 5(1):21-29. PubMed ID: 31693078 [TBL] [Abstract][Full Text] [Related]
19. Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT. Bath PM; Woodhouse LJ; Appleton JP; Beridze M; Christensen H; Dineen RA; Flaherty K; Duley L; England TJ; Havard D; Heptinstall S; James M; Kasonde C; Krishnan K; Markus HS; Montgomery AA; Pocock S; Randall M; Ranta A; Robinson TG; Scutt P; Venables GS; Sprigg N Health Technol Assess; 2018 Aug; 22(48):1-76. PubMed ID: 30179153 [TBL] [Abstract][Full Text] [Related]
20. Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. Bousser MG; Amarenco P; Chamorro A; Fisher M; Ford I; Fox K; Hennerici MG; Mattle HP; Rothwell PM; Cerebrovasc Dis; 2009; 27(5):509-18. PubMed ID: 19372653 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]